TM NASDAQ: PAVM CORPORATE PRESENTATION Fall 2016 1 Disclaimers This presentation contains certain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from r

TM NASDAQ: PAVM CORPORATE PRESENTATION Fall 2016 1

Disclaimers This presentation contains certain forward-looking

statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed

in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those

discussed in "Risk Factors" in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed

with the Securities and Exchange Commission. We undertake no obligation to update publicly any forward-looking statements to reflect

new information, events, or circumstances after the date they were made. This presentation shall not constitute an offer to sell

or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdictions in which

such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such

jurisdiction. PAVmed has not yet sought nor received clearance from the FDA or any other regulatory agency for any of the products

described in this presentation. More information is available at www.pavmed.com or by contacting la@pavmed.com 2

Innovative multi-product medical device company employing

a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly

less capital than the typical medical device company. 3

Investment Highlights Unique, proven business model focused

on capital efficiency and speed to market Deep, expanding pipeline of innovative products across a broad spectrum of clinical

conditions with clear paths to near-term commercialization Attractive market opportunities for lead products totaling over $4

billion Leadership team of entrepreneurs with a strong track record of value creation 4

Leadership team with strong record of value creation LISHAN

MICHAEL BRIAN AKLOG, MD GLENNON DEGUZMAN, MD CHAIRMAN & CEO VICE CHAIRMAN CHIEF MEDICAL OFFICER A.B. Physics, magna B.A.,Business

B.S.Biology cum laude Administration Phi Beta Kappa M.D., cum laude Endoscopy and M.D. Surgical Instrument General Surgery ORIGIN

Territory Sales Resident MEDSYSTEMS Manager General Surgery Cardiothoracic Surgery Resident Resident Cardiac Surgery Assistant

Professor Territory and Regional CardiacSurgery Associate Surgeon Sales Manager Research Fellow CRM Sales Manager Cardiothoracic

Surgery Associate Chief of Resident Cardiac Surgery CRM District Sales Assistant Professor Manager Clinical Associate Director

of Minimally Invasive Cardiac Associate Surgeon Surgery Senior Vice President, AssistantProfessor of Sales and Marketing Surgery

Chair of the Cardiovascular Center FoundingPartner Associate Chief of Chief of CEO, Vortex Medical, Cardiovascular Surgery Cardiovascular

Surgery Saphena Medical and Assistant Professor of Associate Professor of Cruzar Medical Surgery Surgery Senior Advisor, Director

Kaleidoscope FoundingPartner FoundingPartner Medical CMO, Vortex Medical Chairman and CTO, CEO, Kaleidoscope Vortex Medical Medical

Senior Advisor, Senior Advisor, Director Director, Saphena Saphena Medical and Medical, Kaleidoscope Cruzar Medical Medical and

Lead products provide near-term value creation opportunities

PortIO CarpX Implantable Vascular Access Device Percutaneous Carpal Tunnel Device NextCath DisappEAR Self-Anchoring Short-Term

Catheters Resorbable Antibiotic-Eluting Ear Tubes NextFlo Caldus Disposable Tissue Ablation Devices Highly Accurate Infusion System

(*)PAVmed has not yet sought nor received clearance from the FDA or any other regulatory agency for any of these products. 6

The PAVmed Business Model 7

Proven record of capital efficiency and speed to market TIME

AND CAPITAL TO FDA CLEARANCE PAVmed Model 23 months Typical Company 60months 0 12 24 36 48 60 Months PAVmed Model $3 million Typical

Company $31 million $0 $10,000,000 $20,000,000 $30,000,000 Dollars (*)Typical Company data from Markower, et al. FDA Impact on

US Medical Technology Innovation 2010 8

Commercial opportunity drives project selection criteria Reimbursement

Profile High Margin Product Technology Profile Commercial Opportunity Unmet Clinical Need Attractive Market Regulatory Profile

Key business processes deliver capital and time efficiency Outsourced

Parallel Regulatory Best-in-class Development Strategy Process Experts Processes Capital Speed To Efficiency Market Light Flexible

Infrastructure Commercialization Low Fixed Costs Strategy 10

Multi-product strategy enhances value creation Economies Of

Risk Mitigation Scale Flexible, Dynamic Non-binary Allocation Of Success Resources Enhanced Value Creation 11

Flexible commercialization strategy accelerates value creation

Remain Opportunistic Initiate Accelerate To Maximize Commercialization Revenue Growth Value Creation INDEPENDENT CORPORATE CORPORATE

REGULATORY DISTRIBUTOR PARTNER PARTNER CLEARANCE NETWORK Sales and Distribution Licensing agreement Call-point specific Agreement

Acquisition of product DIRECT SALES FORCE Call-point specific 12

Lead Product Development Pipeline 13

Lead products provide near-term value creation opportunities

COMMERCIALIZATION REGULATORY PRODUCT ADDRESSABLE MARKET INITIAL TARGET PATH CHANNEL DATE PortIO Independent Q2 Long-term Implantable

Vascular Access Ports $500M 510(k) Distributors 2017 Vascular Access Devices CarpX Percutaneous Treatment Carpal Tunnel Independent

Q3 $1B 510(k) of Carpal Tunnel Syndrome Distributors 2017 Syndrome Independent Q3 EndovenousAblation $240M 510(k) Distributors

2017 Caldus Independent Q3 Disposable Tissue Fistulae $300M 510(k) Distributors 2017 Ablation Devices CE Mark / Independent Q3

Renal Denervation $1B Emerging Markets Distributors 2018 NextCath Corporate Percutaneous Drainage Q3 Self-Anchoring Short- $200M

510(k) Distribution Catheters 2017 Term Catheters Agreement DisappEAR Independent Q3 Antibiotic-eluting Pediatric Ear Tubes $300M

510(k) Distributors 2018 Resorbable Ear Tubes NextFlo Corporate Disposable Infusion Q4 Highly Accurate $500M 510(k) Distribution

Pumps 2017 Disposable Infusion Pump Agreement (*)PAVmed has not yet sought nor received clearance from the FDA or any other regulatory

agency for any of these products. 14

Vascular Access Devices CLINICAL OVERVIEW MARKET OPPORTUNITY

Long-term Short-term ~7 million central vascular access devices (US) Weekto Months Days to Week ~400-500,000 implantable ports

(US) Chemotherapy, antibiotics, intravenous nutrition, Acute in-hospitalinfusions, biologics and other medications emergency,

trauma Implantable Ports TunneledCentral PeripherallyInserted Central Venous ("Port-a-Cath") Venous Catheter Central

Catheter (PICC) Catheter (CVC) UNMET CLINICAL NEED CURRENT DEVICE LIMITATIONS Limitations driven by intravascular component, 25%

overall complication rate Occlusion Infection Up to 35% incidenceof device occlusion Up to10% incidence of infections More serious

complications (thrombosis, embolism) Half are life-threatening bloodstream infections Requires clot-busting medications or a repeat

Chemotherapy patient especially high-risk procedure Poor Veins Resource Utilization >10% with inaccessible scarred central

veins Surgical insertion and removal Kidney failure patients on dialysis Radiographic confirmation of tip placement Prior chemotherapy

or other need for access Maintenance including regular flushes Patients with pacemaker and defibrillators leads Infections are

costly CMS "Never Events" 15

PortIO The PAVmed Solution INTRAOSSEOUS VASCULAR ACCESS IMPLANTABLE

INTRAOSSEOUS PORT Infusion directly into the bone marrow cavity NO INTRAVASCULAR COMPONENT Rapid, direct drainage into central

venous circulation via Subcutaneous, implantable intraosseous vascular access nutrient/emissary veins Self-tapping/drilling hollow

bone screw, septum, body with internal conical needle guide but no reservoir, "Non-collapsible" vascular access route

Implanted into cortical bone over a guide through a small skin incision Infusion needle inserted through skin, septum and channel

directly accessing bone marrow cavity Well established infusion route for adults and children trauma, military, emergency setting

Bioequivalent to intravenous infusion Few contraindications, low complication rates Target commercialization Q2 2017 Expanding

use in non-emergent clinical scenarios Initial target poor venous access patients Fewer Complications Less Invasive Fewer occlusions

Simple, near-percutaneous insertion and removal Potential for fewer, less serious infections More Cost Effective More Versatile

No need for regular flush Rapid, predictable, repeatable No radiographic confirmation Near limitless number of potential access

sites critical in Shift procedures out of OR to less expensive locale patients those with poor veins 16

Carpal Tunnel Syndrome CLINICAL OVERVIEW MARKET OPPORTUNITY

Estimated prevalence 3-8% of adults = 5 million Estimated $1 billion market Not considering 1.4M patients/year who choose not

to >3M office visits per year undergo surgery but might consider percutaneous approach Over 600,000 U.S. procedures annually

Most common cumulative trauma disorder Half of all occupational injuries in the U.S. and over $20 billion in annual workers' compensation

costs Inflammation of transverse carpal ligament leads to entrapment of the median nerve and hand pain, numbness and weakness

UNMET CLINICAL NEED CURRENT LIMITATIONS TraditionalSurgery is Invasive Endoscopic Surgery is Less Effective Up to 2 inch incision

Remains a surgical procedure Open surgical procedure performed in an operating room performed in an operating Higher recurrence

rate room Higher reoperation rate Post-operative pain Increased nerve injury Atleast 3-4 month recovery Higher costs 17

CarpX The PAVmed Solution PERCUTANEOUS DEVICETOTREAT CARPAL

TUNNEL SYNDROME NO SURGICAL INCISION Balloon catheter with bipolar radiofrequency cutting electrode Device inserted into tunnel

percutaneously over a guidewire under ultrasound guidance Balloon inflated, stretching the ligament over the electrodes and pushing

the median nerve safely away Electrode activated, cleanly cutting ligament from inside out in <1.5 sec with no visible injury

to surrounding structures Successful completion of pre-clinical cadaver study demonstrating reliable and effective transection

of the transverse carpal ligament, replicating anatomic result of traditional, invasive carpal tunnel surgery Completing commercial

design, expect to begin pre-submission validation/verification testing in 2016 Target commercialization Q3 2017 Fewer Complications

Less Invasive Better nerve protection Truly percutaneous Greater lateral dissection may decrease recurrence rates No surgical

incision or dissection No riskof infection Less pain, scarring and recovery time More Cost Effective Expanded Market Shift procedures

to interventional lab or office Lower threshold for intervention for patients "suffering in Shorten procedural times silence",